Meeting
2022 ASCO Annual Meeting
Insights of clinical significance from solid tumor profiles with FoundationOne CDx.
Authors
Andreas M Heilmann
Foundation Medicine, Inc., Cambridge, MA
Andreas M Heilmann , Jonathan W. Riess , Molly McLaughlin-Drubin , James Creeden , Brian Michael Alexander , Rachel Erlich
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3126)
DOI
10.1200/JCO.2022.40.16_suppl.3126
Abstract #
3126
Poster Bd #
118
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Incorporating HER2/HER3 targeted therapies across solid tumors: Assessing the impact of digital education on clinician practice patterns.
First Author: Tariqa Ackbarali
First Author: Mohamed E. Salem
Poster
2024 ASCO Breakthrough
A pan-tumor description of the genomic, transcriptomic, and immunological landscape of sodium-glucose cotransporter-2 (SGLT2) and association with clinical outcomes.
First Author: Heng Tan
Poster
2024 ASCO Annual Meeting
Results from phase 1a/1b analyses of TTX-080, a first in class HLA-G antagonist, in combination with cetuximab in patients (pts) with metastatic colorectal cancer and head and neck squamous cell carcinoma.
First Author: Susanna Varkey Ulahannan